Meissa raises $30M to take RSV vaccine into the clinic

Meissa Vaccines has raised $30 million to advance a pipeline of vaccines to prevent viral respiratory infections. The series A equips Meissa to run phase 1 and 2 trials of a respiratory syncytial virus vaccine.